Literature DB >> 22248874

Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.

Faruk Tas1, Serkan Keskin, Ahmet Karadeniz, Nergiz Dağoğlu, Fatma Sen, Leyla Kilic, Ibrahim Yildiz.   

Abstract

OBJECTIVE: Compared to the cutaneous melanoma, noncutaneous melanomas are relatively rare and have a distinct pattern of behavior. We performed this study to define the clinical characteristics and outcomes of patients with noncutaneous melanomas and emphasize how they differ from cutaneous melanomas.
METHODS: 216 patients who were diagnosed with noncutaneous melanoma were assessed and their medical records between 2000 and 2010 were retrieved from the cancer registry. 475 patients with cutaneous melanoma were used for comparison.
RESULTS: Of the 216 noncutaneous melanoma patients, 83 had mucosal melanoma, 101 had ocular melanoma and 32 had unknown primaries. For mucosal melanoma, the head and neck was the most common anatomic site (53%), followed by the gastrointestinal tract (37%), female genital (6%) and urinary tract (4%). The majority of the ocular melanomas (94%) originated in the uvea. 32 patients demonstrated a primary unknown disease with regional metastasis as the dominant behavior (72%). Age was found to be statistically significantly different among melanoma patients (p < 0.001). Younger patients had more cutaneous and unknown primary melanomas, whereas older patients had more ocular and mucosal melanoma. In subset analyses, we found significant differences between cutaneous and ocular (p = 0.038) or mucosal (p < 0.001) melanomas. The ratios of metastasis on admission were higher in patients with mucosal (27.7%) and unknown primary (28.1%) melanomas, and lower for ocular (3%) melanomas (p < 0.001). Patients with cutaneous melanoma had an intermediate (12%) ratio. Patients with ocular melanoma had better outcome than patients with other melanoma sites (p < 0.05). While overall survival for cutaneous melanoma was significantly negatively correlated with male gender (p < 0.001), advanced stages (p < 0.001) and old age (p = 0.005), stage IV disease was the only independent prognostic factor in patients with ocular melanoma (p = 0.006). No prognostic factor for outcome was found for either mucosal or unknown primary melanomas.
CONCLUSION: The clinical presentations and prognoses of different primary sites of melanoma are distinctive. Therefore, approaches to these melanomas should be different.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22248874     DOI: 10.1159/000334863

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  15 in total

1.  Melanoma of the Oral Cavity: an Analysis of 46 New Cases with Emphasis on Clinical and Histopathologic Characteristics.

Authors:  Molly Housley Smith; Indraneel Bhattacharyya; Donald M Cohen; Nadim M Islam; Sarah G Fitzpatrick; Lindsay J Montague; Douglas D Damm; Craig B Fowler
Journal:  Head Neck Pathol       Date:  2016-01-11

2.  Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study.

Authors:  Gerd Grözinger; Steven Mann; Tarun Mehra; Bernhard Klumpp; Ulrich Grosse; Konstantin Nikolaou; Claus Garbe; Stephan Clasen
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

3.  Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncology.

Authors:  Ozlem Ercelep; Turkan Ozturk Topcu; Ibrahim Vedat Bayoglu; Ahmet Siyar Ekinci; Sinan Koca; Halil Kavgaci; Melike Ozcelik; Ahmet Alacacioglu; Sernaz Uzunoglu; Oktay Bozkurt; Arife Ulas; Asude Aksoy; Burcu Yapar Taskoylu; Ozge Gumussay; Sebnem Yaman; Mukremin Uysal; Dincer Aydin; Mahmut Gumus
Journal:  Tumour Biol       Date:  2016-05-12

4.  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

Authors:  Sandra P D'Angelo; James Larkin; Jeffrey A Sosman; Celeste Lebbé; Benjamin Brady; Bart Neyns; Henrik Schmidt; Jessica C Hassel; F Stephen Hodi; Paul Lorigan; Kerry J Savage; Wilson H Miller; Peter Mohr; Ivan Marquez-Rodas; Julie Charles; Martin Kaatz; Mario Sznol; Jeffrey S Weber; Alexander N Shoushtari; Mary Ruisi; Joel Jiang; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

5.  Burden of illness for metastatic melanoma in Canada, 2011-2013.

Authors:  D S Ernst; T Petrella; A M Joshua; A Hamou; M Thabane; S Vantyghem; F Gwadry-Sridhar
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

6.  Immunotherapy for Melanoma.

Authors:  Justin T Moyers; Isabella C Glitza Oliva
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  The Tumor Suppressor p53 in Mucosal Melanoma of the Head and Neck.

Authors:  Marie Kristin Fritsche; Andreas Knopf
Journal:  Genes (Basel)       Date:  2017-12-13       Impact factor: 4.096

8.  Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

Authors:  Lorena Incorvaia; Giuseppe Badalamenti; Gaetana Rinaldi; Juan Lucio Iovanna; Daniel Olive; Mirna Swayden; Lidia Terruso; Bruno Vincenzi; Fabio Fulfaro; Viviana Bazan; Antonio Russo; Daniele Fanale
Journal:  Ther Adv Med Oncol       Date:  2019-05-13       Impact factor: 8.168

9.  Surgical Treatment of Sinonasal Mucosal Melanoma in Patients Treated with Systemic Immunotherapy.

Authors:  Tiffany N Chao; Edward C Kuan; Charles C L Tong; Michael A Kohanski; M Sean Grady; James N Palmer; Nithin D Adappa; Bert W O'Malley
Journal:  J Neurol Surg B Skull Base       Date:  2020-02-07

10.  Primary gastric melanoma: case report of a rare malignancy.

Authors:  Alexander Augustyn; Emma Diaz de Leon; Adam C Yopp
Journal:  Rare Tumors       Date:  2015-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.